Sep. 10—UPMC Enterprises is investing in a New York company that uses artificial intelligence and robotic retinal imaging in the early detection of eye and other diseases.

Optain Health, a health care technology company, on Wednesday announced the closing of an oversubscribed $26 million Series A fundraising round, which was led by global software investor Insight Partners with participation from UPMC, Ohio State University Wexner Medical Center and New York City-based Northwell Health and others.

Optain was co-created in 2023 by Aegis Ventures, which also formed the Aegis Digital Consortium, a collaboration of 11 leading U.S. health systems to co-develop AI-driven healthtech companies.

UPMC Enterprises, the commercialization and venture capital arm of the Downtown-based health system giant, joined Aegis last year.

Optain uses a portable robotic camera to quickly capture retinal images and integrated AI to detect vision-threatening eye diseases, including diabetic retinopathy, glaucoma and age-related macular degeneration. The platform can also assess the risk of cardiovascular disease.

"Early retinal screening for diabetic retinopathy and chronic disease closes a critical care gap," physician John Noseworthy, chair of the Aegis Digital Consortium, said in a prepared statement. "By deploying Optain in patient care and investing in the company, consortium members have shown strong confidence in its value for enabling early detection and better outcomes."

The health system opened the UPMC Mercy Eye Pavilion in May 2023, which is located on the UPMC Mercy Hospital Uptown campus. The UPMC Vision Institute is housed at the pavilion, where a wide range of vision-related services are offered at a first of its kind center in Western Pennsylvania.